Grail Partners With Junction on Digital Ordering for Galleri Test

Digital health platforms and clinical organizations can now order the Galleri test through Junction's platform.

Junction, a digital infrastructure provider for diagnostic testing, has announced a collaboration with GRAIL to support ordering of the Galleri multi-cancer early detection test.

The partnership, announced April 9, allows healthcare organizations to order the test directly through Junction, manage testing workflows, and access physician follow-up calls with patients. No financial terms for the collaboration were disclosed.

“Junction’s infrastructure helps simplify the operational steps around offering Galleri, making it easier for providers to integrate the test into care delivery,” Megan Hall, Grail’s VP of medical affairs, said in a statement.

Junction’s platform handles the operational steps involved in lab testing, from ordering and specimen collection coordination to results delivery and device data streaming, and serves healthcare organizations across telehealth, longevity, women’s health, research, and clinical care.

The deal follows a $325 million private placement of Grail stock with investors including Hims & Hers, an online, consumer-driven health platform which will offer Galleri.